VERA THERAPEUTICS INC (VERA) Stock Analyst Ratings
NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 83% to VERA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 68.68. This target is 80.4% above the current price.
VERA was analyzed by 18 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about VERA.
In the previous month the buy percentage consensus was at a similar level.
VERA was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-02-04 | Wolfe Research | Initiate | Outperform |
| 2024-11-21 | Wells Fargo | Initiate | Overweight |
| 2024-11-08 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-28 | Guggenheim | Maintains | Buy -> Buy |
| 2024-10-16 | ScotiaBank | Initiate | Sector Outperform |
| 2024-10-03 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-10-01 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-23 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-05-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-05-10 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2024-04-05 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-03-27 | Guggenheim | Maintains | Buy -> Buy |
| 2024-03-21 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-01-26 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-01-26 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2024-01-25 | Oppenheimer | Initiate | Outperform |
| 2024-01-08 | Cantor Fitzgerald | Initiate | Overweight |
| 2023-12-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-18 | Raymond James | Initiate | Outperform |
| 2023-11-30 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-11-10 | Jefferies | Upgrade | Hold -> Buy |
| 2023-09-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-16 | Guggenheim | Initiate | Buy |
| 2023-08-11 | Wedbush | Maintains | Neutral -> Neutral |